Evidence map›Paper›PMID 41587967›Full record

ArticleNature communications2026

Computational design of generalist cyclopropanases with stereodivergent selectivity.

Zhuofan Shen, Mary G Siriboe, Xinkun Ren, Thakshila Dayananda, Jermaine L Jenkins, Sagar D Khare, Rudi Fasan

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhuofan Shen *Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Mary G Siriboe *Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA.
Xinkun Ren *Department of Chemistry, University of Rochester, Rochester, NY, USA.
Thakshila DayanandaDepartment of Chemistry, University of Rochester, Rochester, NY, USA.ORCID http://orcid.org/0000-0003-3726-7780
Jermaine L JenkinsDepartment of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.ORCID http://orcid.org/0000-0003-2548-3275
Sagar D KhareDepartment of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, Piscataway, NJ, USA. sagar.khare@rutgers.edu.
Rudi FasanDepartment of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA. rudi.fasan@utdallas.edu.ORCID http://orcid.org/0000-0003-4636-9578

Funding

A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
Selective P450 Oxidation Catalysts for Synthesis of Bioactive MoleculesR01GM098628 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI FASAN, RUDI · 2012 to 2024
$4.7M
Chemoenzymatic Strategies for Molecular Discovery and Asymmetric SynthesisR35GM158365 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI Rudi Fasan · 2025 to 2026
$1.2M
NIH Training Grant in Chemistry-Biology InterfaceT32GM145461 · NIGMS · UNIVERSITY OF ROCHESTER · PI KARA L. BREN, Bradley L. Nilsson · 2022 to 2026
$988k
NIH Training Grant in the Chemistry-Biology InterfaceT32GM118283 · NIGMS · UNIVERSITY OF ROCHESTER · PI BREN, KARA L., FASAN, RUDI · 2017 to 2021
$850k
NIGMS NIH HHS P30 GM133894NIGMS NIH HHS R01 GM098628NIGMS NIH HHS R35 GM158365NIGMS NIH HHS T32 GM118283NIGMS NIH HHS T32 GM145461U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R01GM098628U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM158365Welch Foundation AT-0051-20221212
6 · The paper itself

Abstract

Stereodivergent catalysis, whereby the full complement of stereoisomeric products is obtained through a set of stereocomplementary catalysts, represents a powerful tool for synthetic organic and medicinal chemistry. Despite recent progress in engineering biocatalysts for new-to-nature cyclopropanation reactions, cyclopropanases featuring a combination of stereodivergent selectivity with broad substrate scope have been elusive. Here, we report a mechanism-based, multi-state computational design workflow useful for the design of 'generalist' cyclopropanation biocatalysts with tailored selectivity. Using this strategy, cyclopropanases with high and predictable trans-(1 R,2 R), cis-(1 R,2S), or cis-(1S,2 R)-stereoselectivity in the transformation of a broad range of olefin substrates are designed based on three different hemoprotein scaffolds, including one (indoleamine 2,3-dioxygenase-1) not previously reported to support non-native carbene transfer reactions. Combined with a previously reported trans-(1S,2S)-stereoselective cyclopropanase, this biocatalytic toolbox provides access to a full set of cyclopropane stereoisomers from over 20 structurally diverse olefin substrates with high diastereo- and enantioselectivity (up to 99% de. and 99% ee). Crystal structures of a designed catalyst show good agreement with the computational model and highlight the role of subtle conformational heterogeneity in determining stereoselectivity. We envision that the present computational design methodology can guide the development of biocatalysts with tailored stereoselectivity for other carbene transfer reactions and enzymatic transformations.

Indexed as

CyclopropanesAlkenesBiocatalysisModels, MolecularStereoisomerismSubstrate SpecificityAlkenesCyclopropanes

Identifiers

PMID41587967
PMCPMC12905309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.